[
  {
    "ts": null,
    "headline": "Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx",
    "summary": "Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, offering substantial discounts on several drugs as part of a federal push on pricing. For you as an investor, this puts NYSE:PFE at the intersection of two important themes in healthcare: vaccines and drug affordability. Matrix-M is designed to boost immune response in vaccines, and access to...",
    "url": "https://finnhub.io/api/news?id=d05fb1ea1b410b272d55c13310fab036d4b06085419840cc7714210b8a880e9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769721089,
      "headline": "Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx",
      "id": 138300121,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, offering substantial discounts on several drugs as part of a federal push on pricing. For you as an investor, this puts NYSE:PFE at the intersection of two important themes in healthcare: vaccines and drug affordability. Matrix-M is designed to boost immune response in vaccines, and access to...",
      "url": "https://finnhub.io/api/news?id=d05fb1ea1b410b272d55c13310fab036d4b06085419840cc7714210b8a880e9c"
    }
  },
  {
    "ts": null,
    "headline": "Carbapenem-resistant Enterobacteriaceae Infection Market - A Global and Regional Analysis: Focus Country and Regional Analysis, 2025-2035",
    "summary": "The global carbapenem-resistant Enterobacteriaceae (CRE) infection market is experiencing robust growth due to the rising prevalence of multidrug-resistant Gram-negative infections and heightened awareness of antimicrobial resistance. Key drivers include the approval of next-generation antibiotics like Cefiderocol and institutional support in regions like North America. Increased healthcare spending and advanced therapeutic demand bolster market expansion from 2025-2035. However, high treatment",
    "url": "https://finnhub.io/api/news?id=1ee268e520629e58ef3de86e9b5cceff60f8a6757d3101d2f61e414b3f9d7bae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769698200,
      "headline": "Carbapenem-resistant Enterobacteriaceae Infection Market - A Global and Regional Analysis: Focus Country and Regional Analysis, 2025-2035",
      "id": 138295704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global carbapenem-resistant Enterobacteriaceae (CRE) infection market is experiencing robust growth due to the rising prevalence of multidrug-resistant Gram-negative infections and heightened awareness of antimicrobial resistance. Key drivers include the approval of next-generation antibiotics like Cefiderocol and institutional support in regions like North America. Increased healthcare spending and advanced therapeutic demand bolster market expansion from 2025-2035. However, high treatment",
      "url": "https://finnhub.io/api/news?id=1ee268e520629e58ef3de86e9b5cceff60f8a6757d3101d2f61e414b3f9d7bae"
    }
  },
  {
    "ts": null,
    "headline": "Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
    "summary": "Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "url": "https://finnhub.io/api/news?id=0e383834f2c3b544a8dc6233a02f78d4f859882f1e3d8b64b0eb40192951daa3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769696102,
      "headline": "Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
      "id": 138295705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
      "url": "https://finnhub.io/api/news?id=0e383834f2c3b544a8dc6233a02f78d4f859882f1e3d8b64b0eb40192951daa3"
    }
  },
  {
    "ts": null,
    "headline": "3 High-Yield Stocks to Buy Hand Over Fist in January",
    "summary": "If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close.",
    "url": "https://finnhub.io/api/news?id=b668ae32daa595824c90f2eb34afd0c2e4adccebe9432385a6ece4e9d8205ff4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769689380,
      "headline": "3 High-Yield Stocks to Buy Hand Over Fist in January",
      "id": 138294638,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close.",
      "url": "https://finnhub.io/api/news?id=b668ae32daa595824c90f2eb34afd0c2e4adccebe9432385a6ece4e9d8205ff4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: A High-Yield Pharma At A Turning Point",
    "summary": "Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why PFE stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=ea773c0df2a52f5a28c6fe2da838c9ea509d4f6789a120078f8d1a8b0101e264",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769677200,
      "headline": "Pfizer: A High-Yield Pharma At A Turning Point",
      "id": 138295067,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202955977/image_1202955977.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why PFE stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=ea773c0df2a52f5a28c6fe2da838c9ea509d4f6789a120078f8d1a8b0101e264"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to its Matrix-M adjuvant tech. This technology is designed to boost immune responses to vaccines and will be utilized by Pfizer for up to two infectious […]",
    "url": "https://finnhub.io/api/news?id=79fe086c66cd2c4102909b46b4d56a8ad1592ba3269c69a02f92f52b32be30fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769670460,
      "headline": "Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline",
      "id": 138292633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to its Matrix-M adjuvant tech. This technology is designed to boost immune responses to vaccines and will be utilized by Pfizer for up to two infectious […]",
      "url": "https://finnhub.io/api/news?id=79fe086c66cd2c4102909b46b4d56a8ad1592ba3269c69a02f92f52b32be30fa"
    }
  },
  {
    "ts": null,
    "headline": "This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years",
    "summary": "After a years-long revenue drought, there's a light at the end of the tunnel.",
    "url": "https://finnhub.io/api/news?id=4a5ba52c82a43ada5370ff1e9bc18ba1ec4803520a2e476e506b324b870e0642",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769646180,
      "headline": "This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years",
      "id": 138291096,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "After a years-long revenue drought, there's a light at the end of the tunnel.",
      "url": "https://finnhub.io/api/news?id=4a5ba52c82a43ada5370ff1e9bc18ba1ec4803520a2e476e506b324b870e0642"
    }
  }
]